Ibrutinib Contributes Heightened Risk of Developing Hypertension, Study Reveals

A study has revealed that the use of ibrutinib seems to contribute to a heightened risk of developing hypertension or high blood pressure.

Ibrutinib Contributes Heightened Risk of Developing Hypertension, Study Reveals
Photo: Blood Pressure Checking | InStyleHealth


Research analysis involved 144 patients with B cell malignancies, of whom 93 were treated with ibrutinib while 51 were given conventional chemoimmunotherapy. Blood pressure levels were assessed at months 1, 2, 3, and 6 after initiation of treatment.

Hypertension was common in both ibrutinib and control groups, with no marked difference. Age, gender, and baseline cardiac comorbidities were similar in the two treatment groups.

The systolic and diastolic blood pressure significantly increased over time in the ibrutinib group but remained stable in the control group. Hypertension status at baseline showed no effect on the degree of blood pressure change over time.

During the first month of follow-up, there was a significant increase in systolic blood pressure (BP) levels (>10mm Hg) that occurred more often in the ibrutinib than in the control group, result shows 36.6% vs 7.9%.

Regarding hypertension management, it appears more than half of the patients, around 61.2%, in the ibrutinib group that did not receive adequate BP management, whether increase or addition of BP medications, despite being hypertensive during follow-up. Moreover, for those who showed elevations of >20mm Hg in systolic BP, only 52.9% did undergo hypertension management changes.

In relation to the outcomes of the retrospective analysis, cardiologists and oncologists should monitor patients on ibrutinib for timely management of blood pressure elevations.

 

Source: Heart 2021;doi:10.1136/heartjnl-2021-319110

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post